The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MC1923 phase II clinical trial of durvalumab (MEDI4736) and topotecan or lurbinectedin in patients with relapsed extensive-stage small cell lung cancer previously treated with chemotherapy and immunotherapy.
 
Konstantinos Leventakos
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Mirati Therapeutics (Inst); MJH Life Sciences (Inst); OncLive (Inst); Regeneron (Inst); Takeda (Inst); Targeted Oncology (Inst)
Research Funding - AstraZeneca (Inst); Mirati Therapeutics (Inst)
 
Anastasios Dimou
Honoraria - Intellisphere; Intellisphere (Inst); Intellisphere (Inst); Roche/Genentech
Consulting or Advisory Role - TP Therapeutics (Inst)
Research Funding - Novartis (Inst); Syntrix Biosystems (Inst)
Other Relationship - Rising Tide Foundation (Inst)
 
Nathan R. Foster
No Relationships to Disclose
 
Lynn M. Flickinger
No Relationships to Disclose
 
Sri Harsha Tella
No Relationships to Disclose
 
Julian R. Molina
No Relationships to Disclose
 
Aaron Scott Mansfield
Honoraria - Roche
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst)
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Abbvie; Roche
 
Randolph Marks
No Relationships to Disclose
 
Anna J Schwecke
No Relationships to Disclose
 
Craig Hocum
No Relationships to Disclose
 
Jenesse Nicole Moffett
No Relationships to Disclose
 
Ashley Potter
No Relationships to Disclose
 
Alex A. Adjei
Research Funding - Bayer Schering Pharma (Inst); I-Mab (Inst); Jacobio (Inst); Kura Oncology (Inst); Merck KGaA (Inst); Tesaro (Inst); Zai Lab (Inst)
(OPTIONAL) Uncompensated Relationships - Merck KGaA; Swiss Rockets; Zai Lab